POSEIDA THERAPEUTICS INC (PSTX)
US73730P1084 - Common Stock
PSTX gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 571 industry peers in the Biotechnology industry. PSTX may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, PSTX is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
PSTX had negative earnings in the past year.
In the past year PSTX has reported a negative cash flow from operations.
In the past 5 years PSTX always reported negative net income.
PSTX had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
Looking at the Return On Assets, with a value of -20.70%, PSTX is in the better half of the industry, outperforming 77.60% of the companies in the same industry.
PSTX's Return On Equity of -69.67% is in line compared to the rest of the industry. PSTX outperforms 57.50% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.7% | ||
| ROE | -69.67% | ||
| ROIC | N/A |
ROA(3y)-36.56%
ROA(5y)-40.69%
ROE(3y)-77.72%
ROE(5y)-80.34%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for PSTX so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
PSTX does not have a ROIC to compare to the WACC, probably because it is not profitable.
PSTX has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PSTX has more shares outstanding
PSTX has a worse debt/assets ratio than last year.
2.2 Solvency
PSTX has an Altman-Z score of -1.68. This is a bad value and indicates that PSTX is not financially healthy and even has some risk of bankruptcy.
PSTX's Altman-Z score of -1.68 is in line compared to the rest of the industry. PSTX outperforms 55.20% of its industry peers.
A Debt/Equity ratio of 0.68 indicates that PSTX is somewhat dependend on debt financing.
PSTX has a worse Debt to Equity ratio (0.68) than 76.01% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.68 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.68 |
ROIC/WACCN/A
WACC10.64%
2.3 Liquidity
A Current Ratio of 3.20 indicates that PSTX has no problem at all paying its short term obligations.
PSTX's Current ratio of 3.20 is on the low side compared to the rest of the industry. PSTX is outperformed by 62.08% of its industry peers.
PSTX has a Quick Ratio of 3.20. This indicates that PSTX is financially healthy and has no problem in meeting its short term obligations.
PSTX's Quick ratio of 3.20 is on the low side compared to the rest of the industry. PSTX is outperformed by 60.32% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.2 |
3. Growth
3.1 Past
PSTX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.28%, which is quite impressive.
Looking at the last year, PSTX shows a very strong growth in Revenue. The Revenue has grown by 202.93%.
EPS 1Y (TTM)58.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%160%
Revenue 1Y (TTM)202.93%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%667.19%
3.2 Future
The Earnings Per Share is expected to grow by 13.53% on average over the next years. This is quite good.
Based on estimates for the next years, PSTX will show a very strong growth in Revenue. The Revenue will grow by 38.04% on average per year.
EPS Next Y8.09%
EPS Next 2Y-15.25%
EPS Next 3Y-2.25%
EPS Next 5Y13.53%
Revenue Next Year124.96%
Revenue Next 2Y-3.31%
Revenue Next 3Y-22%
Revenue Next 5Y38.04%
3.3 Evolution
4. Valuation
4.1 Price/Earnings Ratio
PSTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PSTX. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PSTX's earnings are expected to decrease with -2.25% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.25%
EPS Next 3Y-2.25%
5. Dividend
5.1 Amount
No dividends for PSTX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
POSEIDA THERAPEUTICS INC
NASDAQ:PSTX (11/26/2024, 7:04:08 PM)
After market: 9.36 -0.02 (-0.21%)9.38
+6.52 (+227.97%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap914.27M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -20.7% | ||
| ROE | -69.67% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.51
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.68 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.2 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)58.28%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y8.09%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)202.93%
Revenue growth 3YN/A
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y